← Back to Screener
Novavax Inc (NVAX)
Price$8.84
Favorite Metrics
Price vs S&P 500 (26W)-2.62%
Price vs S&P 500 (4W)-17.60%
Market Capitalization$1.44B
P/E Ratio (Annual)3.27x
All Metrics
Book Value / Share (Quarterly)$0.23
P/TBV (Annual)11.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-17.24%
Cash Flow / Share (Quarterly)$-1.54
Price vs S&P 500 (YTD)27.41%
Gross Margin (TTM)93.50%
Net Profit Margin (TTM)39.19%
EPS (TTM)$2.37
10-Day Avg Trading Volume2.82M
EPS Excl Extra (TTM)$2.37
Revenue Growth (5Y)18.76%
EPS (Annual)$2.54
ROI (Annual)-38.19%
Gross Margin (Annual)93.50%
Net Profit Margin (5Y Avg)-45.81%
Cash / Share (Quarterly)$4.52
P/E Basic Excl Extra (TTM)3.27x
Revenue Growth QoQ (YoY)66.61%
P/E Normalized (Annual)3.27x
ROA (Last FY)-12.02%
Revenue Growth TTM (YoY)64.69%
EBITD / Share (TTM)$2.79
ROE (5Y Avg)-43.51%
Operating Margin (TTM)37.75%
Cash Flow / Share (Annual)$-0.63
P/B Ratio38.28x
P/B Ratio (Quarterly)27.12x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)1.29x
Net Interest Coverage (TTM)20.61x
ROA (TTM)35.32%
EV / EBITDA (TTM)2.94x
EPS Incl Extra (Annual)$2.54
Current Ratio (Annual)0.98x
Quick Ratio (Quarterly)2.04x
3-Month Avg Trading Volume4.54M
52-Week Price Return42.58%
P/E Incl Extra (TTM)3.27x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$0.78
P/S Ratio (Annual)1.28x
Asset Turnover (Annual)0.44x
52-Week High$11.97
Operating Margin (5Y Avg)-47.20%
EPS Excl Extra (Annual)$2.54
CapEx CAGR (5Y)-36.67%
Tangible BV CAGR (5Y)66.48%
26-Week Price Return6.12%
Quick Ratio (Annual)0.92x
13-Week Price Return7.94%
Total Debt / Equity (Annual)0.75x
Current Ratio (Quarterly)2.13x
Enterprise Value$1,448.531
Revenue / Share Growth (5Y)-4.70%
Asset Turnover (TTM)0.90x
Book Value / Share Growth (5Y)-0.67%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)8.00x
Pretax Margin (Annual)39.36%
Cash / Share (Annual)$5.77
3-Month Return Std Dev80.12%
Gross Margin (5Y Avg)66.92%
Net Income / Employee (TTM)$1
ROE (Last FY)-66.69%
Net Interest Coverage (Annual)20.61x
EPS Basic Excl Extra (Annual)$2.54
P/FCF (TTM)13.62x
Receivables Turnover (TTM)10.46x
Total Debt / Equity (Quarterly)6.07x
EPS Incl Extra (TTM)$2.37
Receivables Turnover (Annual)5.18x
ROI (TTM)40.02%
P/S Ratio (TTM)1.28x
Pretax Margin (5Y Avg)-44.86%
Revenue / Share (Annual)$6.49
Tangible BV / Share (Annual)$8.75
Forward P/E77.23x
Price vs S&P 500 (52W)7.49%
P/E Ratio (TTM)3.27x
Year-to-Date Return31.55%
5-Day Price Return9.00%
EPS Normalized (Annual)$2.54
ROA (5Y Avg)-33.11%
Net Profit Margin (Annual)39.19%
Month-to-Date Return8.60%
Cash Flow / Share (TTM)$-5.39
EBITD / Share (Annual)$2.84
Operating Margin (Annual)37.75%
LT Debt / Equity (Annual)0.51x
ROI (5Y Avg)-37.60%
P/E Excl Extra (TTM)3.27x
LT Debt / Equity (Quarterly)4.53x
EPS Basic Excl Extra (TTM)$2.37
P/TBV (Quarterly)92.41x
P/B Ratio (Annual)11.32x
Inventory Turnover (TTM)7.20x
Pretax Margin (TTM)39.36%
Book Value / Share (Annual)$8.83
Price vs S&P 500 (13W)5.07%
Beta2.55x
P/FCF (Annual)5.43x
Revenue / Share (TTM)$5.98
ROE (TTM)283.08%
52-Week Low$5.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.67
3.67
3.67
3.67
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NVAXNovavax Inc | 1.28x | 64.69% | 93.50% | — | $8.84 |
AMGNAmgen Inc | 5.21x | 9.95% | 73.30% | 2.93% | $355.30 |
GILDGilead Sciences Inc | 5.80x | 2.40% | 78.83% | 133.64% | $137.64 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $849.04 |
BNTXBioNTech SE American Depositary Share | 8.99x | -11.81% | 84.21% | — | $102.92 |
BIIBBiogen Inc. Common Stock | 2.63x | 2.22% | 75.69% | -18.77% | $177.35 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $53.72 |
NBIXNeurocrine Biosciences Inc | 4.68x | 21.45% | 98.18% | 2.31% | $133.25 |
EXELExelixis Inc | 5.02x | 6.85% | 96.39% | 31.10% | $44.89 |
TECHBio-Techne Corp. | 7.62x | 1.64% | 66.60% | -20.58% | $59.23 |
HALOHalozyme Therapeutics, Inc. | 5.88x | 37.55% | 83.62% | 22.89% | $69.29 |
About
Novavax Inc is a biotechnology company developing vaccines to prevent a broad range of human infectious diseases, with a focus on both established and emerging disease threats. The company conducts clinical-stage development of novel vaccine candidates, supported by its Swedish subsidiary's manufacturing operations. Its proprietary vaccine technology platform is designed for broad applicability across multiple infectious disease indications, with the majority of revenue generated from the United States.